These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28845514)

  • 21. Neoadjuvant hormonal therapy in carcinoma of the prostate.
    Lee HH; Warde P; Jewett MA
    BJU Int; 1999 Mar; 83(4):438-48. PubMed ID: 10210568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy.
    Kitagawa Y; Koshida K; Mizokami A; Komatsu K; Nakashima S; Misaki T; Katsumi T; Namiki M
    Int J Urol; 2003 Jul; 10(7):377-82. PubMed ID: 12823692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neoadjuvant hormonal therapy versus surgery alone for radical prostatectomy in high-risk prostate cancer patients].
    Kobayashi M; Saito Y; Komaru A; Fukasawa S; Suyama T; Akakura K; Ichikawa T; Ueda T
    Hinyokika Kiyo; 2013 Jul; 59(7):411-8. PubMed ID: 23945319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant hormonal therapy prior to radical prostatectomy: evaluation of pathological downstaging and biochemical relapse.
    Kiriyama I; Ogaki K; Ohba S; Nishimura T
    J Nippon Med Sch; 2002 Oct; 69(5):422-7. PubMed ID: 12382001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
    Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
    Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure.
    Brown JA; Garlitz C; Strup SE; Hubosky SG; Gomella L
    J Laparoendosc Adv Surg Tech A; 2004 Dec; 14(6):335-8. PubMed ID: 15684777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity is a predictor in prostate cancer patients receiving prostatectomy after neoadjuvant hormonal therapy.
    Sun L; Xu T; Yuan X; Liu F; Guan F; Ye D; Zhang G
    Tumori; 2020 Apr; 106(2):133-138. PubMed ID: 31451070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [8-month neoadjuvant hormonal therapy before radical prostatectomy for high-risk prostate cancer].
    Tabata K; Satoh T; Matsumoto K; Fujita T; Irie A; Iwamura M; Yanagisawa N; Matsuda D; Muramoto M; Kadowaki K; Suyama K; Shoji K; Koh H; Kawakami T; Okayasu I; Egawa S; Baba S
    Nihon Hinyokika Gakkai Zasshi; 2006 Jul; 97(5):712-8. PubMed ID: 16898594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy.
    Ogawa O; Iinuma M; Sato K; Sasaki R; Shimoda N; Satoh S; Kato T
    Urol Res; 1999 Aug; 27(4):291-6. PubMed ID: 10460902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    Qian H; Chi C; Tricard T; Zhu Y; Dong L; Wang Y; Sha J; Wang J; Ma Z; Wang Y; Liu J; Dong B; Pan J; Xue W
    J Urol; 2024 May; 211(5):648-655. PubMed ID: 38591703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination approach using neoadjuvant therapy with radical prostatectomy for improving oncological outcomes of high-risk prostate cancer: a narrative review.
    Nakane K; Kawase M; Kato D; Iinuma K; Kawase K; Takeuchi S; Tobisawa Y; Ito T; Koie T
    Transl Cancer Res; 2024 Jul; 13(7):3889-3897. PubMed ID: 39145084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
    Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
    Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
    Fair WR; Betancourt JE
    Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate Stem Cell Antigen Expression in Radical Prostatectomy Specimens Predicts Early Biochemical Recurrence in Patients with High Risk Prostate Cancer Receiving Neoadjuvant Hormonal Therapy.
    Kim SH; Park WS; Kim SH; Park B; Joo J; Lee GK; Joung JY; Seo HK; Chung J; Lee KH
    PLoS One; 2016; 11(3):e0151646. PubMed ID: 26982980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Hormonal Therapy for Prostate Cancer: Morphologic Features and Predictive Parameters of Therapy Response.
    Wang X; Zhang J; Han B
    Adv Anat Pathol; 2022 Jul; 29(4):252-258. PubMed ID: 35670702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
    Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Furukawa J; Miyake H; Takenaka A; Hara I; Fujisawa M
    BJU Int; 2007 Aug; 100(2):310-4. PubMed ID: 17511772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis.
    Liu W; Yao Y; Liu X; Liu Y; Zhang GM
    Asian J Androl; 2021; 23(4):429-436. PubMed ID: 33586699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.